Advertisement · 728 × 90
#
Hashtag
#Humacyte
Advertisement · 728 × 90
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 day ago
Preview
Investigation into Alleged Breach of Fiduciary Duties by Humacyte, Inc. Executives Halper Sadeh LLC is probing potential breaches of fiduciary duties by Humacyte, Inc.'s leadership, raising concerns for long-term shareholders.

Investigation into Alleged Breach of Fiduciary Duties by Humacyte, Inc. Executives #USA #New_York #Humacyte #Inc. #Halper_Sadeh #fiduciary_duties

0 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
9 months ago
Humacyte stock soars after Symvess gains DOD electronic catalog listing Investing.com -- Humacyte Inc (NASDAQ:HUMA) stock surged 21% after the company announced that its Symvess product received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and patients receiving care at Department of Defense (DOD) and U.S. Department of Veterans Affairs facilities. This listing provides these federal agencies with direct access to the company’s bioengineered human tissue product. Symvess, described as an acellular tissue engineered vessel, received FDA approval for extremity vascular trauma indication in December 2024. The product is part of Humacyte’s commercial-stage biotechnology platform that develops universally implantable, bioengineered human tissue. "We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families," said Dr. Laura Niklason, President and CEO of Humacyte. "We have received positive feedback in our interactions with a number of DOD hospitals, and we look forward to making Symvess available to more patients in need." The company noted that for uses beyond the FDA-approved extremity vascular trauma indication, the acellular tissue engineered vessel remains an investigational product that has not received regulatory approval. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is HUMA one of them?

Click Subscribe #Humacyte #Symvess #StockMarket #Investing #DODElectronicCatalog

0 0 0 0
Profit Trading USA
Profit Trading USA
@profittradingusa.bsky.social
1 year ago
Humacyte CEO addresses concerns in NYT over FDA approval of Symvess Investing.com -- Dr. Laura Niklason, President and CEO of Humacyte, Inc. (NASDAQ:HUMA), responded to a New York Times (NYSE:NYT) article that questioned the FDA’s approval of Symvess for commercial sales earlier this week. Niklason had previously withheld comment due to the company being in a quiet period while finalizing a new round of financing. The FDA’s review of the Biologics License Application (BLA) for Symvess, a process that took over a year, was highlighted by Niklason. During this period, the FDA considered convening an Advisory Committee of outside experts after Dr. Robert E. Lee, a consultant on the file, raised concerns. However, the FDA decided against this, instead opting for extensive internal consultation and seeking perspectives from three experienced vascular surgeons outside the agency. Despite the original Prescription Drug User Fee Act (PDUFA) date being August 10, 2024, the FDA took an additional 19 weeks to complete its review of Symvess. After considering all views, the FDA approved Symvess on December 19, 2024, deeming it safe and effective for use in repair of vascular trauma of the extremities when autologous vein grafting is not feasible. Niklason praised the FDA’s review process, noting that it was conservative and time-consuming, as it should be. She also disclosed that Humacyte is committed to conducting a post-approval study to further assess the rate and severity of adverse events in trauma patients treated with Symvess. The company remains confident that this study will confirm the safety and effectiveness of Symvess, as demonstrated in two previous trials. In response to the New York Times’ reliance on Dr. Lee as a primary source, Niklason clarified that he was not part of the formal review team for Symvess at the FDA. She also pointed out that Dr. Lee had resigned from the FDA in late September, prior to the FDA’s decision to approve Symvess. Niklason also took issue with the New York Times’ coverage on other points, such as the claim that ruptures of synthetic grafts are unheard of and that shrapnel wounds are not typically seen on the battlefield. She refuted these claims, citing her own experience and data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database. Niklason reaffirmed Humacyte’s commitment to safety and the effectiveness of its product. In a civilian trauma trial of Symvess, which treated patients with severe injuries, the results were excellent, with an independent safety review committee attributing any instances of amputation or patient death to the underlying injuries and complications, not Symvess. Niklason concluded by highlighting that over the past 12 years, Humacyte’s engineered vessels have treated more than 600 patients in 9 separate clinical studies, none of which have been halted for safety concerns. She expressed optimism for the future of Symvess in treating trauma patients in the United States. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #FDAApproval #Biotechnology #HealthcareInnovation #InvestingNews #Humacyte

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Important Class Action Lawsuit Notifies Humacyte, Inc. Investors Ahead of Deadline Levi & Korsinsky has alerted investors about a class-action lawsuit against Humacyte, highlighting key allegations and important upcoming deadlines.

Important Class Action Lawsuit Notifies Humacyte, Inc. Investors Ahead of Deadline #United_States #New_York #Class_Action #Humacyte #Levi_Korsinsky

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte Faces Class Action Lawsuit Over Securities Violations Impacting Investors Humacyte, Inc. is embroiled in a class action lawsuit for alleged securities law violations, prompting affected investors to take action.

Humacyte Faces Class Action Lawsuit Over Securities Violations Impacting Investors #United_States #Humacyte #Los_Angeles #HUMA #DJS_Law_Group

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Legal Action: Humacyte, Inc. Offers Investors Chance to Lead Securities Fraud Class Action Investors affected by losses in Humacyte, Inc. can lead a securities fraud class action lawsuit. Key details and participation options inside.

Legal Action: Humacyte, Inc. Offers Investors Chance to Lead Securities Fraud Class Action #United_States #Class_Action #Humacyte #Los_Angeles #Securities_Fraud

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Gross Law Firm Alerts Humacyte Shareholders of Class Action Lawsuit and Important Deadline The Gross Law Firm has announced a class action lawsuit for Humacyte, Inc. shareholders, detailing allegations and a critical registration deadline on January 17, 2025.

Gross Law Firm Alerts Humacyte Shareholders of Class Action Lawsuit and Important Deadline #United_States #New_York #Class_Action #Gross_Law_Firm #Humacyte

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Faruqi & Faruqi, LLP Takes Action for Humacyte Investors Facing Losses Faruqi & Faruqi, LLP is investigating claims against Humacyte, Inc., urging investors who suffered over $75,000 in losses to respond before the deadline.

Faruqi & Faruqi, LLP Takes Action for Humacyte Investors Facing Losses #USA #New_York #Humacyte #Investor_Rights #Faruqi_&_Faruqi

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Pomerantz Law Firm Files Class Action Against Humacyte, Inc. Over Investment Losses The Pomerantz Law Firm has initiated a class action lawsuit against Humacyte, Inc., urging shareholders affected by investment losses to take action by upcoming deadlines.

Pomerantz Law Firm Files Class Action Against Humacyte, Inc. Over Investment Losses #United_States #New_York #Class_Action #Humacyte #Pomerantz_LLP

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte Investors Facing Losses Can Lead Class Action Against Securities Fraud Allegations Humacyte investors reporting significant losses now have the chance to spearhead a class action lawsuit regarding securities fraud. Find out how.

Humacyte Investors Facing Losses Can Lead Class Action Against Securities Fraud Allegations #United_States #Humacyte #Securities_Fraud #Bensalem #Lawsuit

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Join the Class Action Against Humacyte, Inc. Before the Deadline of January 17, 2025 Investors in Humacyte, Inc. are urged to join an ongoing class action lawsuit targeting securities fraud related to the company's operations.

Join the Class Action Against Humacyte, Inc. Before the Deadline of January 17, 2025 #United_States #New_York #Levi_&_Korsinsky #Humacyte #Inc. #securities_lawsuit

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors Can Lead Class Action Against Humacyte for Securities Fraud Allegations Rosen Law Firm announces an opportunity for Humacyte investors to lead a securities fraud class action lawsuit, with legal deadlines approaching.

Investors Can Lead Class Action Against Humacyte for Securities Fraud Allegations #USA #New_York #Humacyte #Securities_Fraud #Rosen_Law_Firm

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors in Humacyte, Inc. Gain Chance to Lead Securities Fraud Lawsuit Humacyte, Inc. (NASDAQ: HUMA) investors facing losses are being called to lead a securities fraud class action lawsuit. Key details about the lawsuit and participation opportunities are outlined.

Investors in Humacyte, Inc. Gain Chance to Lead Securities Fraud Lawsuit #United_States #Class_Action #Humacyte #Los_Angeles #fraud

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors Rally for Humacyte's Securities Class Action Lawsuit Amid Manufacturing Concerns The Schall Law Firm invites investors of Humacyte, Inc. to join a class action lawsuit addressing alleged securities fraud linked to manufacturing issues.

Investors Rally for Humacyte's Securities Class Action Lawsuit Amid Manufacturing Concerns #USA #Humacyte #Los_Angeles #Schall_Law_Firm #Securities_Class_Action

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors Alert: Class Action Against Humacyte, Inc. for Misleading Statements A class action lawsuit has been filed against Humacyte, Inc. for alleged misleading statements that affected shareholders. Shareholders have until January 17, 2025, to join.

Investors Alert: Class Action Against Humacyte, Inc. for Misleading Statements #USA #New_York #Class_Action #Humacyte #SEC_Lawsuit

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte, Inc. Investors Urged to Join Class Action Lawsuit by Levi & Korsinsky Levi & Korsinsky LLP is reminding Humacyte, Inc. investors about an impending class action lawsuit, providing essential details and deadlines for participation.

Humacyte, Inc. Investors Urged to Join Class Action Lawsuit by Levi & Korsinsky #USA #New_York #Class_Action #Humacyte #Levi_Korsinsky

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors in Humacyte, Inc. Urged to Act Before January 2025 Deadline for Rights Discussion The Gross Law Firm alerts Humacyte, Inc. investors to register by January 17, 2025, regarding potential misstatements during the class period affecting share value.

Investors in Humacyte, Inc. Urged to Act Before January 2025 Deadline for Rights Discussion #United_States #New_York #Gross_Law_Firm #Humacyte #HUMA

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Pomerantz Law Firm Announces Class Action Against Humacyte, Inc. for Investors with Losses Investors in Humacyte, Inc. facing losses can join a class action lawsuit announced by Pomerantz Law Firm, with a deadline of January 17, 2025.

Pomerantz Law Firm Announces Class Action Against Humacyte, Inc. for Investors with Losses #United_States #New_York #Humacyte #Pomerantz #ClassAction

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Faruqi & Faruqi Urges Humacyte Investors to Act Before January 2025 Deadline Faruqi & Faruqi, a prominent law firm, is reminding Humacyte investors of an important deadline related to a pending class action lawsuit set for January 2025.

Faruqi & Faruqi Urges Humacyte Investors to Act Before January 2025 Deadline #USA #New_York #Class_Action #Humacyte #Faruqi_&_Faruqi

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Levi & Korsinsky Alerts Humacyte, Inc. Investors About Class Action Lawsuit Deadline of January 2025 Levi & Korsinsky notifies investors in Humacyte, Inc. of a class action lawsuit with a lead plaintiff deadline approaching on January 17, 2025.

Levi & Korsinsky Alerts Humacyte, Inc. Investors About Class Action Lawsuit Deadline of January 2025 #United_States #New_York #Class_Action #Humacyte #HUMA

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Opportunity for HUMA Investors to Join Humacyte, Inc. Fraud Lawsuit with Schall Law Firm HUMA investors are invited to join a class action lawsuit against Humacyte, Inc. for alleged securities fraud. Learn how to participate in the case.

Opportunity for HUMA Investors to Join Humacyte, Inc. Fraud Lawsuit with Schall Law Firm #United_States #Humacyte #Los_Angeles #Schall_Law_Firm #Securities_Fraud

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte, Inc. Faces Lawsuit Over Alleged Securities Violations, Shareholders Urged to Act Humacyte, Inc. is under scrutiny for securities law violations. Affected shareholders are encouraged to contact The Gross Law Firm for assistance and to potentially become lead plaintiffs.

Humacyte, Inc. Faces Lawsuit Over Alleged Securities Violations, Shareholders Urged to Act #USA #New_York #The_Gross_Law_Firm #Humacyte #HUMA

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Rosen Law Firm Offers Guidance on Humacyte Securities Fraud Class Action Investors of Humacyte, Inc. are urged to participate in a securities fraud class action lawsuit with a lead plaintiff deadline on January 17, 2025.

Rosen Law Firm Offers Guidance on Humacyte Securities Fraud Class Action #United_States #New_York #Humacyte #Securities_Fraud #Rosen_Law_Firm

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte, Inc. Faces Class Action Lawsuit for Alleged Securities Fraud - Important for Investors to Know Humacyte, Inc. is facing a class action lawsuit related to securities fraud affecting investors. Key details and contact information for affected investors inside.

Humacyte, Inc. Faces Class Action Lawsuit for Alleged Securities Fraud - Important for Investors to Know #United_States #New_York #Levi_&_Korsinsky #Humacyte #HUMA

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Humacyte, Inc. Faces Securities Fraud Class Action Lawsuit from Investors Seeking Justice Investors of Humacyte, Inc. have the chance to lead a securities fraud class action lawsuit. Join the movement to hold the company accountable.

Humacyte, Inc. Faces Securities Fraud Class Action Lawsuit from Investors Seeking Justice #USA #Class_Action #Humacyte #Los_Angeles #Securities_Fraud

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Legal Action Initiated for Humacyte, Inc. Shareholders in Securities Class Action Case The Gross Law Firm has filed a securities class action for Humacyte, Inc. shareholders, highlighting misleading statements and potential risks to FDA approval.

Legal Action Initiated for Humacyte, Inc. Shareholders in Securities Class Action Case #United_States #New_York #Gross_Law_Firm #Humacyte #Securities_Class_Action

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Pomerantz Law Firm Warns Humacyte Investors About Class Action Lawsuit Deadlines Pomerantz LLP has filed a class action lawsuit against Humacyte, Inc., urging investors with losses to seek membership by January 17, 2025.

Pomerantz Law Firm Warns Humacyte Investors About Class Action Lawsuit Deadlines #United_States #New_York #Class_Action #Humacyte #Pomerantz_Law_Firm

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors Alert: Humacyte, Inc. Faces Class Action Lawsuit for Securities Violations Humacyte, Inc. is under scrutiny for alleged securities law violations during a specified class period. Investigate your rights with DJS Law Group.

Investors Alert: Humacyte, Inc. Faces Class Action Lawsuit for Securities Violations #United_States #Humacyte #HUMA #DJS_Law_Group #Eastchester

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Investors Urged to Act Promptly Amid Humacyte Securities Investigation Deadline Faruqi & Faruqi, LLP is currently investigating potential claims against Humacyte, urging affected investors to act ahead of the January deadline.

Investors Urged to Act Promptly Amid Humacyte Securities Investigation Deadline #United_States #New_York #Humacyte #Faruqi_&_Faruqi #NASDAQ_HUMA

0 0 0 0
Thiard News@F4F
Thiard News@F4F
@newsen.bsky.social
1 year ago
Preview
Shareholders of Humacyte, Inc. Urged to Act by January 17, 2025 in Ongoing Class Action Lawsuit Levi & Korsinsky LLP reminds Humacyte investors of a lead plaintiff deadline related to securities litigation set for January 17, 2025.

Shareholders of Humacyte, Inc. Urged to Act by January 17, 2025 in Ongoing Class Action Lawsuit #United_States #New_York #Levi_&_Korsinsky #Humacyte #Securities_Fraud

0 0 0 0